FDA’s Circulatory System Devices advisory panel overwhelmingly recommended approval of Boston Scientific Corp.’s PMA for the Watchman left atrial appendage (LAA) closure device as an alternative to warfarin therapy for stroke prevention in some atrial fibrillation patients.
Watchman is intended to prevent embolism from the left atrial appendage that could cause stroke, systemic embolism, and cardiovascular death...